Skip to content

Assessment of Serum Leptin in Vitiligo Patients

Assessment of Serum Leptin in Vitiligo Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05549869
Enrollment
400
Registered
2022-09-22
Start date
2022-11-30
Completion date
2023-09-30
Last updated
2022-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Detailed description

, leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators such as tumor necrosis factor α TNF, IL-2 and IL-6, as well as enhancing cytotoxic T cells CD8 recruitment and inhibiting the functions of regulatory T cells Tregs. Leptin can also aid in induction of oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase• Venous blood samples will be taken from patients and controls to evaluate serum leptin: Morning samples will be taken after 12-h overnight fast in plain vacutainer tubes and directly centrifuged (1098 g for 15 min). * Sera will be then collected in plain, capped, 5 ml centrifuge tubes Eppendorf and freezed at -20ᵒC in a well-monitored freezer until the analysis is performed• Serum leptin will be quantitatively assessed in vitro using DRG leptin Sandwich Enzyme Linked Immuno-Sorbent Assay ELISA. * ELISA will be performed according to manufacturer's guidelines where each run included a standard curve. * Using the mean absorbance value for each sample, the corresponding concentration from the standard curve will be determined.

Interventions

DIAGNOSTIC_TESTserum leptin

Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients with vitiligo who are above the age of 18 years

Exclusion criteria

* Patients with other autoimmune diseases

Design outcomes

Primary

MeasureTime frameDescription
level of serum leptin6 monthEvaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Countries

Egypt

Contacts

Primary Contactdoaa z amin, resident
doaa_zaghloul_post@med.sohag.edu.eg01019096561
Backup Contactwafaa m Abdel- majeed, Ass.Professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026